NICE backs Novartis’ Aimovig for prevention of episodic and chronic migraine
pharmafile | December 11, 2020 | News story | Medical Communications, Sales and Marketing | Aimovig, NICE, Novartis, migraine
NICE has announced its decision to recommended Novartis’ Aimovig (erenumab) for the prevention of migraine, including both episodic and chronic migraine, on routine NHS use in England and Wales.
An appeal was launched to challenge an earlier decision by NICE to reject the therapy, urging the watchdog to consider the cost-effectiveness of the drug in treating chronic migraine in patients who did not respond adequately to botulinum toxin or when it is contra-indicated.
NICE revisited the case, including new data supplied by Novartis, and believed the evidence base was now sufficient to recommend the use of the drug in adult patients who experience at least four migraine days each month and who have not seen their condition improve despite receiving at least three previous preventive treatments.
While Aimovig costs around ÂŁ5,000 per patient per year, the NHS has agreed with Novartis to access the drug at a confidential discounted price.
NICE is anticipated to publish final guidance on its decision in January next year.
Matt Fellows
Related Content
Novartis shares new data about Fabhalta for IgAN treatment
Novartis has announced new results from a pre-specified interim analysis of its phase 3 APPLAUSE-IgAN …
NICE recommends migraine treatment for NHS use
The National Institute for Health and Care Excellence (NICE) has shared draft guidance recommending AbbVie’s …
GSK’s Jemperli recommended by NICE for endometrial cancer treatment
GSK has announced that the National Institute for Health and Care Excellence (NICE) has recommended …